Auto-injector device

DEVICE2 trials

Sponsors

Amgen, Regeneron Pharmaceuticals

Conditions

Atopic DisordersEczema, AtopicHealthy Men and Women

Phase 1

Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection

CompletedNCT02799498

AmgenHealthy Men and Women

Start: 2003-10-31End: 2004-01-31Updated: 2016-06-15

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

CompletedNCT03050151

Regeneron PharmaceuticalsAtopic Disorders, Eczema, Atopic

Start: 2017-02-28End: 2018-02-12Updated: 2018-08-01

Related Papers

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).

2022-05-1470 citations

Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.

2019-10-08105 citations